GURU.Markets stock price, segment price, and overall market index valuation
The company's share price NexImmune Inc.
Nicholas Financial is a company that provides auto loans to customers with less-than-perfect credit. Its stock price is cyclical and depends on the state of the economy and unemployment, which affect borrowers' creditworthiness.
Share prices of companies in the market segment - Oncology immuno-therapy
NexImmune is developing a new form of immunotherapy using nanoparticles to activate T cells and combat cancer and other diseases. We've categorized it as "Immuno-Oncology," and the chart below shows how the market is valuing this cutting-edge, yet high-risk, biotech sector.
Broad Market Index - GURU.Markets
NexImmune is developing a new form of immunotherapy using nanoparticles to activate T cells and combat cancer and other diseases. We've categorized it as "Immuno-Oncology," and the chart below shows how the market is valuing this cutting-edge, yet high-risk, biotech sector.
Change in the price of a company, segment, and market as a whole per day
NEXI - Daily change in the company's share price NexImmune Inc.
For NexImmune, Inc., an immuno-oncology company, daily price change is a measure of extreme volatility. It reflects the market's reaction to clinical trial data and is a critical parameter in risk assessment formulas.
Daily change in the price of a set of shares in a market segment - Oncology immuno-therapy
NexImmune is developing a new approach to immunotherapy targeting T cells for the treatment of cancer and other diseases. This sector is one of the most advanced and volatile in biotech. The chart below reflects the average fluctuations in this industry, serving as a benchmark for NEXI stock valuation.
Daily change in the price of a broad market stock, index - GURU.Markets
NexImmune is a biotech company developing cancer immunotherapy drugs. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization NexImmune Inc.
NexImmune, Inc.'s year-over-year performance is a story of its unique immunotherapy platform. Its 12-month market cap is entirely dependent on early clinical trial data. The success of its approach, which uses artificial antigen-presenting cells, could be a breakthrough in cancer treatment.
Annual dynamics of market capitalization of the market segment - Oncology immuno-therapy
NexImmune, as an early-stage biotech, is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials of its immunotherapy. Its stock price will reflect investors' speculative faith in the potential of its unique developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
NexImmune, a biopharmaceutical company developing a new approach to cancer immunotherapy, is a story of cutting-edge science. Its year-over-year market capitalization reflects investor faith in its technology platform, not the state of the economy.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization NexImmune Inc.
NexImmune is an immuno-oncology company. Its monthly performance is driven by progress in clinical trials of its unique platform. Positive data from its programs, presented at conferences, is the main driver of its valuation.
Monthly dynamics of market capitalization of the market segment - Oncology immuno-therapy
NexImmune is a biotech company developing a new approach to cancer immunotherapy that uses artificial antigen-presenting cells to "train" T cells. The graph below illustrates the overall dynamics of the immunotherapy sector, where breakthrough technologies are constantly being sought to combat cancer.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Biotech stocks often live in a world of their own, where clinical trial news trumps overall market trends. The chart below shows the pulse of the broader market. Does NexImmune, Inc. move in unison with it, or do its R&D developments create a completely independent story?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization NexImmune Inc.
The weekly performance of NexImmune, an immuno-oncology company, reflects the company's search for new approaches to cell therapy. Its stock price is responding to data from preclinical and clinical trials of its platform, which aims to create more specific T cells to fight cancer.
Weekly dynamics of market capitalization of the market segment - Oncology immuno-therapy
NexImmune is developing a novel approach to cancer immunotherapy targeting T cells. This chart compares its volatile, data-driven performance with the immuno-oncology sector and helps us understand how much investors believe in its unique scientific platform against a diverse set of competitors.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
NexImmune is a biotech company. Its shares can be highly volatile and sensitive to research news. This chart will help you understand whether NexImmune is living in its own world of clinical trials, or whether the overall market environment and risk appetite in biotech are influencing its stock price.
Market capitalization of the company, segment and market as a whole
NEXI - Market capitalization of the company NexImmune Inc.
NexImmune's market capitalization tells the story of a biotech company developing T-cell immunotherapy. Its decline on the chart is a tale of clinical failures and subsequent restructuring. The dynamics are a clear example of how quickly hopes can be dashed in this risky industry.
NEXI - Share of the company's market capitalization NexImmune Inc. within the market segment - Oncology immuno-therapy
NexImmune is a biotech company working on cancer immunotherapy. Its small share of the overall sector market cap reflects its early stage of development. The chart shows how much its weight depends on clinical trial results and investor confidence in its scientific approach.
Market capitalization of the market segment - Oncology immuno-therapy
NexImmune is a biotech company developing a new approach to cancer immunotherapy. The chart below shows the overall market capitalization of this research-intensive sector. Its volatile dynamics reflect the hopes and risks that accompany the long journey to developing breakthrough drugs.
Market capitalization of all companies included in a broad market index - GURU.Markets
NexImmune is a biotech company focused on immuno-oncology. Its market cap reflects the hope that its unique approach to T-cell activation will help fight cancer. Its volatility on the overall chart reflects high risks and potential breakthroughs at the cutting edge of science.
Book value capitalization of the company, segment and market as a whole
NEXI - Book value capitalization of the company NexImmune Inc.
NexImmune's book value represents its capital invested in developing a unique immunotherapy based on artificial antigen-presenting cells for the treatment of cancer and autoimmune diseases. This is the tangible, scientific foundation for a new approach to medicine. How has this biotech asset changed? The chart below shows its dynamics.
NEXI - Share of the company's book capitalization NexImmune Inc. within the market segment - Oncology immuno-therapy
NexImmune is developing a new approach to immunotherapy, which requires cutting-edge biotech laboratories. The chart shows the share of these science-intensive tangible assets, reflecting the physical foundation on which the company is building its technological platform.
Market segment balance sheet capitalization - Oncology immuno-therapy
NexImmune, a development-stage biopharmaceutical company, has minimal physical assets. Its business is focused on R&D. The BCap_Seg chart for the biotech sector, which consists of hundreds of similar companies, is generally low, as its primary capital is intellectual capital.
Book value of all companies included in the broad market index - GURU.Markets
NexImmune's balance sheet isn't the drugs on the shelf, but its AIM scientific platform for developing next-generation cancer immunotherapies. The company's assets are its intellectual capital, patents, and preclinical data. The chart shows how this science-intensive R&D asset stacks up against big pharma.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - NexImmune Inc.
For NexImmune, a company working in immunotherapy, the balance sheet is the value of its scientific platform and research. Market valuation is the sheer hope of developing an effective cancer cure. The MvsBCap_Co chart reflects investor confidence in its scientific approach and potential to transform patients' lives.
Market to book capitalization ratio in a market segment - Oncology immuno-therapy
NexImmune is a biotech company developing a novel approach to cancer immunotherapy. Its market valuation on the chart is entirely speculative and reflects investors' faith in its scientific platform and potential for future clinical results, not its current assets.
Market to book capitalization ratio for the market as a whole
NexImmune, Inc., an immuno-oncology company, invests in scientific research. Its current market valuation is essentially a bet investors make on the future success of its therapeutic platforms. This chart provides context for understanding how high expectations are in the biotech sector compared to the market average.
Debts of the company, segment and market as a whole
NEXI - Company debts NexImmune Inc.
NexImmune, a clinical-stage biotech developing a novel cancer immunotherapy platform, is using capital to fund its early-stage research. This chart shows how the company is raising high-risk investments to validate its scientific concept, which could offer a new approach to cancer treatment.
Market segment debts - Oncology immuno-therapy
NexImmune is an early-stage biotech company developing a novel platform for cancer immunotherapy. Funding for such fundamental research is entirely dependent on equity capital. This chart illustrates the industry's typical zero-debt financial model, reflecting the high scientific risk.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio NexImmune Inc.
NexImmune is a biotech company developing a novel approach to cancer immunotherapy. Its technology is in early clinical trials. This chart shows the company's reliance on debt to finance its expensive and risky R&D. It is a direct measure of its financial vulnerability.
Market segment debt to market segment book capitalization - Oncology immuno-therapy
NexImmune is an early-stage biotech company developing a novel approach to cancer immunotherapy. Its technology targets T-cell stimulation. This chart illustrates how aggressively the biotech sector uses debt for R&D, providing context for assessing the risks and potential of this innovative, yet unproven, platform.
Debt to book value of all companies in the market
NexImmune, Inc., a clinical-stage biopharmaceutical company developing immunotherapy, requires significant funding for its research. This chart, reflecting the overall debt burden in the market, provides context for assessing its risks. It demonstrates how the company's capital raising strategy is typical for early-stage biotech companies.
P/E of the company, segment and market as a whole
P/E - NexImmune Inc.
NexImmune is developing a new approach to cancer immunotherapy using nanoparticles to activate T cells. This chart shows how investors value its scientific platform. The company's valuation is based not on profits, but on the results of preclinical and clinical trials, as well as the potential of its technology.
P/E of the market segment - Oncology immuno-therapy
This chart shows the average valuation for biotech companies, providing context for NexImmune. It reflects overall speculative valuations in the sector. Comparisons with these valuations help understand how the market values NexImmune's scientific immunotherapy platform and whether it believes it can deliver on its promise after a challenging period.
P/E of the market as a whole
NexImmune is a biotech company developing immuno-oncology drugs. Its valuation is a pure bet on its scientific platform. It has no connection to the general economic cycles depicted by this chart. NexImmune's value is determined solely by the success or failure of its clinical trials.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company NexImmune Inc.
This chart for NexImmune, Inc., a biopharmaceutical company developing a novel approach to cancer immunotherapy, demonstrates market expectations for its clinical programs. It reflects investor confidence in the potential of its unique artificial antigen-presenting cell technology.
%20P%2FE%20NexImmune%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-NexImmune-Inc.&v=1772666593356 "Chart of the company's future (projected) P/E NexImmune Inc.")
Future (projected) P/E of the market segment - Oncology immuno-therapy
NexImmune is a clinical-stage biopharmaceutical company developing novel T-cell-based immunotherapies for the treatment of cancer and autoimmune diseases. The chart shows forecasts for the oncology sector, allowing investors to compare their confidence in NexImmune's unique technology platform with expectations for other approaches in immuno-oncology.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-immuno-therapy&v=1772666593368 "Future (projected) P/E graph of the market segment - Oncology immuno-therapy")
Future (projected) P/E of the market as a whole
NexImmune, Inc. is a biotech company developing a novel approach to cancer immunotherapy. This company is in very early research stages. Its valuation reflects pure faith in its scientific concept. This overall risk appetite chart demonstrates how favorable the funding environment is for the most daring biotech ideas.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772666593389 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit NexImmune Inc.
NexImmune is developing a new cancer immunotherapy platform based on artificial antigen-presenting cells (AAPs). While in early clinical trials, the company is incurring losses. This chart illustrates the high cost of developing breakthrough oncology technologies and the long journey from scientific idea to patient.
Profit of companies in the market segment - Oncology immuno-therapy
NexImmune is a biotech company developing a new approach to cancer immunotherapy based on the use of artificial antigen-presenting cells (AAPs). This chart, which reflects profitability in the oncology sector, illustrates how science is searching for new ways to activate the immune system. Their platform aims to generate a more specific and powerful T-cell response against tumors.
Overall market profit
NexImmune is developing a new immunotherapy platform aimed at activating T cells to combat cancer and other diseases. Like many early-stage biotech companies, its valuation is based on the potential of its technology. This graph of overall market returns reflects the investment climate, which determines how easily such companies can raise capital.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company NexImmune Inc.
NexImmune is developing a new form of cancer immunotherapy using an artificial antigen-presenting cell (AIM) platform to activate T cells. This graph represents analysts' expectations for the success of clinical trials of this innovative technology, which is a bet on a new approach to fighting cancer.
%20profit%20of%20the%20company%20NexImmune%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-NexImmune-Inc.&v=1772666593567 "Graph of future (projected) profit of the company NexImmune Inc.")
Future (predicted) profit of companies in the market segment - Oncology immuno-therapy
NexImmune is a clinical-stage biotech company developing a novel approach to cancer immunotherapy targeting T cells. Its future depends on the success of its artificial antigen-presenting cell (AIM) platform. This oncology timeline reflects the market's overall confidence in the potential of immunotherapy and new treatment approaches.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-immuno-therapy&v=1772666593604 "Graph of future (predicted) profits of companies in a market segment - Oncology immuno-therapy")
Future (predicted) profit of the market as a whole
NexImmune is a biotech company developing immunotherapy. Its success depends on scientific breakthroughs. However, the overall profit forecast shown in this chart shapes the investment climate. During periods of economic optimism, investors are more inclined to fund high-risk but promising research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772666593659 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - NexImmune Inc.
NexImmune is a clinical-stage biotech developing a novel immunotherapy approach for the treatment of cancer and autoimmune diseases. Without product revenue, this chart is key. It shows how investors evaluate its scientific platform and future revenue potential, betting on a breakthrough in medicine.
P/S market segment - Oncology immuno-therapy
NexImmune is developing a new approach to immunotherapy using nanoparticles to activate T cells to fight cancer and other diseases. The company's valuation is based on the potential of its unique scientific platform. This chart reflects the average valuation in the biotech industry, helping investors understand how expectations for NexImmune's innovative technology align with trends.
P/S of the market as a whole
NexImmune is a biotech company developing a novel approach to cancer immunotherapy using artificial antigen-presenting cells (AAPs) to activate T cells. This chart, which reflects real-world revenue estimates, highlights that NexImmune's valuation is a bet on its breakthrough scientific platform and future clinical success.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company NexImmune Inc.
NexImmune is a clinical-stage biotech company developing a novel immunotherapy platform for the treatment of cancer and autoimmune diseases. Its approach is based on T-cell multiplication. This chart reflects investors' confidence in the potential of its scientific platform to create a new generation of cell therapies in the future.
%20P%2FS%20NexImmune%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-NexImmune-Inc.&v=1772666593753 "The graph of the company's future (projected) P/S NexImmune Inc.")
Future (projected) P/S of the market segment - Oncology immuno-therapy
NexImmune, Inc. is a clinical-stage biopharmaceutical company developing a novel immunotherapy approach aimed at activating T cells to combat cancer and other diseases. This chart reflects average revenue expectations in the immuno-oncology sector and provides insight into the market's appreciation of NexImmune's scientific platform.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-immuno-therapy&v=1772666593774 "Future (projected) P/S market segment graph - Oncology immuno-therapy")
Future (projected) P/S of the market as a whole
NexImmune is developing a new approach to cancer immunotherapy using artificial antigen-presenting cells to activate a patient's T cells. The graph below shows the overall market's revenue growth prospects. The company's innovative platform could offer new treatment options for patients unresponsive to existing therapies.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772666593800 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales NexImmune Inc.
This chart illustrates the revenue of NexImmune, Inc., a clinical-stage biopharmaceutical company developing a novel approach to cancer immunotherapy. Its revenue at this stage consists not of sales but of payments under collaboration agreements. The trend reflects research progress and partner interest in its scientific platform.
Sales of companies in the market segment - Oncology immuno-therapy
NexImmune is developing a new approach to cancer immunotherapy using a platform to create nanoparticles that train the body's T cells to attack tumors. This graph reflects the growth of the oncology market. The company's innovative technology could lead to more effective and personalized treatments, expanding the horizons of the entire field of immuno-oncology.
Overall market sales
NexImmune is a biotech company developing immunotherapy for cancer treatment. Its market cap is based on the potential of its scientific platform. The overall economic situation, reflected in this chart, influences investor willingness to finance long-term, capital-intensive projects in the biotech sector.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company NexImmune Inc.
NexImmune is a biotech company developing a novel approach to cancer immunotherapy targeting T cells. The company's future revenue depends on the success of its clinical programs. The chart reflects analysts' confidence in the potential of its unique technology platform.
%20sales%20of%20the%20company%20NexImmune%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-NexImmune-Inc.&v=1772666593927 "Schedule of future (projected) sales of the company NexImmune Inc.")
Future (projected) sales of companies in the market segment - Oncology immuno-therapy
NexImmune is a biotech company developing a new approach to immunotherapy aimed at activating T cells to fight cancer and other diseases. This chart shows the forecast for the entire immuno-oncology market, where NexImmune aims to create more effective and specific treatments using its unique platform.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-immuno-therapy&v=1772666593993 "Schedule of future (projected) sales of companies in the market segment - Oncology immuno-therapy")
Future (projected) sales of the market as a whole
NexImmune is a clinical-stage biotech company developing a novel T-cell-based immunotherapy for the treatment of cancer and autoimmune diseases. Its valuation is dependent on the success of its scientific platform. This schedule, reflecting sentiment in the biotech sector, impacts the company's ability to attract funding to continue its research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772666594022 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality NexImmune Inc.
NexImmune is a biotech company developing a new generation of immunotherapy for cancer treatment. While in clinical trials, it incurs significant R&D expenses. This chart shows its net losses—the cost of trying to create a breakthrough technology that can "train" the immune system to fight tumors more effectively.
Market segment marginality - Oncology immuno-therapy
NexImmune is a clinical-stage biotech company developing a novel approach to cancer immunotherapy aimed at stimulating T cells. Profitability is a long-term goal. This chart reflects R&D investments. Investors analyze it to assess the potential of their unique platform for creating next-generation drugs.
Market marginality as a whole
NexImmune is a biotech company developing a new approach to cancer immunotherapy that uses artificial antigen-presenting cells to activate T cells. This overall profitability schedule is irrelevant to them. Their value and future depend solely on the results of clinical trials and the potential of their scientific platform.
Employees in the company, segment and market as a whole
Number of employees in the company NexImmune Inc.
NexImmune is a clinical-stage biotech company developing a novel approach to cancer immunotherapy. It operates with a small team of scientists focused on research and development. This timeline reflects its current status as a science-focused, not commercial, company.
Share of the company's employees NexImmune Inc. within the market segment - Oncology immuno-therapy
NexImmune is developing a new approach to cancer immunotherapy aimed at activating T cells. This chart shows the company's share of scientific talent in this cutting-edge biotech field. This growth reflects the expansion of its research platform and progress in developing next-generation anticancer treatments.
Number of employees in the market segment - Oncology immuno-therapy
NexImmune, Inc. is a clinical-stage biopharmaceutical company developing a novel immunotherapy approach targeting T cells. This chart shows the employment dynamics in the cutting-edge field of immuno-oncology. The growing number of scientists here reflects the platform's potential for creating a new generation of treatments for cancer and autoimmune diseases by modulating the immune response.
Number of employees in the market as a whole
NexImmune is a biotech company developing immunotherapy for cancer treatment. Its development is entirely dependent on clinical trial results and capital raising. General economic stability, illustrated by this chart, influences investor willingness to invest in the high-risk biotech sector at early stages.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company NexImmune Inc. (NEXI)
NexImmune is a biotech company developing a new generation of cancer immunotherapy. Like other clinical-stage companies, its staff consists of scientists, and its value is based on expectations. The chart shows the premium the market is willing to pay for the intellectual capital of each employee. This figure reflects not current revenue, but the potential value of their scientific platform and future patents in the fight against cancer.
%20of%20the%20company%20NexImmune%20Inc.%20(NEXI)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-NexImmune-Inc.-NEXI&v=1772666594454 "Chart of market capitalization per employee (in thousands of dollars) of the company NexImmune Inc. (NEXI)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
NexImmune is a biotech company developing a novel immunotherapy approach for the treatment of cancer and autoimmune diseases. Its value is determined by the potential of its scientific platform. This chart demonstrates the high market valuation of its cutting-edge technologies and intellectual property, based on its small team of scientists.
%20by%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-immuno-therapy&v=1772666594488 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology immuno-therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
NexImmune is a biopharmaceutical company developing a novel approach to cancer immunotherapy targeting T cells. The chart illustrates the valuation of their scientific platform. It shows how the market values their unique technology, where the contribution of a small team of scientists can lead to the creation of a powerful new class of drugs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772666594567 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company NexImmune Inc. (NEXI)
NexImmune is a clinical-stage biotech company specializing in the development of a new class of T-cell immunotherapies for cancer treatment. This is R&D. This chart shows capital burn: the amount the company spends on each scientist using their proprietary platform to discover new drugs.
%20Chart%20NexImmune%20Inc.%20(NEXI)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-NexImmune-Inc.-NEXI&v=1772666594637 "Company Profit Per Employee (in thousands of dollars) Chart NexImmune Inc. (NEXI)")
Profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
NexImmune is a clinical-stage biotech company developing a novel platform for cancer immunotherapy. Like most R&D companies, this metric is negative. It reflects targeted investments in research and clinical trials to create breakthrough treatments, not operating losses.
%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-immuno-therapy&v=1772666594743 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy")
Profit per employee (in thousands of dollars) for the market as a whole
NexImmune is a clinical-stage biotech company specializing in cancer immunotherapy. It's an R&D company and has no profit. This chart shows the company's capital burn rate: the operating loss per team of scientists developing a new drug through expensive clinical trials.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772666594826 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee NexImmune Inc. (NEXI)
NexImmune is a biotech company developing a novel approach to cancer immunotherapy. This chart reflects the progress of monetizing its scientific platform. At this stage, revenue is likely generated through partnerships, and the increase in revenue per employee signals the achievement of important clinical milestones and the increasing value of its developments.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-NexImmune-Inc.-NEXI&v=1772666594876 "Sales chart per company employee NexImmune Inc. (NEXI)")
Sales per employee in the market segment - Oncology immuno-therapy
NexImmune is a biotech company developing T-cell therapy using a unique "artificial immune system" platform. While in the clinical stage, their revenue comes from partner fees. This chart shows how productive their R&D team is in attracting capital from major pharma companies per scientist.
Sales per employee for the market as a whole
NexImmune (NEXI) is a clinical-stage biotech company developing an immunotherapy platform for the treatment of cancer and autoimmune diseases. The company has no commercial revenue yet. This chart illustrates a typical R&D situation: an entire staff of highly qualified scientists is working on the development of future drugs, consuming investment capital.
Short shares by company, segment and market as a whole
Shares shorted by company NexImmune Inc. (NEXI)
NexImmune is an early-stage biotech developing a cancer immunotherapy platform. This chart shows bearish sentiment. This is typical for speculative biotechs: investors are betting that its scientific platform will fail to prove effective in clinical trials and the company will fail.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-NexImmune-Inc.-NEXI&v=1772666595012 "Short Shares Chart for the Company NexImmune Inc. (NEXI)")
Shares shorted by market segment - Oncology immuno-therapy
NexImmune is an early-stage biotech developing an immunotherapy platform for the treatment of cancer and autoimmune diseases. Its technology targets T cells. This chart represents the cumulative shortfall across the entire cellular immunotherapy sector. It demonstrates the high level of investor skepticism regarding the clinical success and commercialization of these complex and expensive treatments.
Shares shorted by the overall market
NexImmune (NEXI) is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing NEXI won't be able to raise capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator NexImmune Inc. (NEXI)
This oscillator for NexImmune is a barometer of faith in T-cell therapy. The company is developing a platform for "training" T-cells. "Overheating" (above 70) occurs based on early data. A clinical failure, program shutdowns, and restructuring (layoffs) to preserve cash lead to "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-NexImmune-Inc.-NEXI&v=1772666595154 "RSI 14 indicator chart for the company's stock NexImmune Inc. (NEXI)")
RSI 14 Market Segment - Oncology immuno-therapy
NexImmune (NEXI) is a biotech company developing next-generation T-cell therapies. They aim to create "smart" T-cells to fight cancer. This chart tracks the overall sentiment in the Immuno-Oncology sector. It helps investors understand whether NEXI's performance reflects their science or whether the entire biotech sector is overheated or oversold.
RSI 14 for the overall market
For NexImmune, a biotech company, this graph is a lifeline. Its survival depends on funding R&D. During periods of market euphoria, investors are willing to generously fund risky but promising research. During periods of panic, the money supply is turned off, and cash-burning companies risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast NEXI (NexImmune Inc.)
NexImmune (NEXI) is a clinical-stage biotech developing T-cell-based immunotherapies for cancer. This chart shows the average 12-month forecast. It reflects analysts' speculative valuation of this scientific platform, their expectations for early clinical data, and the company's financial strength (cash burn).
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-NEXI-NexImmune-Inc.&v=1772666595211 "A chart showing analyst consensus forecasts for the expected stock price. NEXI (NexImmune Inc.)")
The difference between the consensus estimate and the actual stock price NEXI (NexImmune Inc.)
NexImmune (NEXI) is a biotech company developing a novel platform (AIM) for the development of T-cell therapy for cancer. This chart shows the difference between the market valuation and the consensus estimate. It highlights the potential (and risks) analysts see in this early-stage R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-NEXI-NexImmune-Inc.&v=1772666595224 "A chart showing the difference between the consensus forecast and the actual stock price. NEXI (NexImmune Inc.)")
Analyst consensus forecast for stock prices by market segment - Oncology immuno-therapy
NexImmune is a biotech company developing "immunotherapy 2.0" (based on T-cells) for cancer treatment. This R&D is at the cutting edge of science, where both risk and potential are high. This chart shows analysts' overall expectations for the *entire* immunotherapy sector. It reflects whether experts believe new breakthroughs are possible or whether they consider the sector overheated.
Analysts' consensus forecast for the overall market share price
NexImmune (NEXI) is a clinical-stage biopharmaceutical company working at the forefront of immuno-oncology. This is a high-risk scientific endeavor. This chart shows the overall risk appetite in the market. It serves as an indicator of the "open" or "closed" funding window for speculative biotechs seeking capital.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index NexImmune Inc.
NexImmune is an immune biotech. Their specialty isn't CAR-T, but rather direct induction (AIM) of T cells (immunity) directly within the patient's body to attack cancer or autoimmune diseases. This chart is purely an indicator of their R&D. It doesn't reflect revenue, but rather a speculative estimate of their scientific progress and clinical trial data.
AKIMA Market Segment Index - Oncology immuno-therapy
NexImmune is an immuno-oncology company. They are developing T-cell therapy (based on the AIM AI platform) that trains the immune system to attack cancer. In this hot sector, standing out is crucial. This chart compares their composite index to the sector, showing how their technology platform outperforms the competition.
The AKIM Index for the overall market
NexImmune is a biotech company developing nanoparticle-based immunotherapy (AIM) for the treatment of cancer and autoimmune diseases. It is undergoing liquidation/restructuring. This chart, which reflects the market average, provides a macro backdrop. It helps assess how the distressed biotech stock compares to overall economic trends.
